Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Allogene Gets Pfizer's Off-The-Shelf CAR-T Program, $300m Series A Backing

Executive Summary

Celgene reworks its collaboration with Abide, dropping its buyout option. Roivant gains Chinese rights to anti-infective lemafulin and adds a fifth candidate to Dermavant's pipeline, while pSivida acquires Icon and FDA-approved Dexycu for cataract surgery inflammation.
Advertisement

Related Content

Compugen Concentrates On Pipeline After AZ Antibody Pact
Nichi-Iko Aims For ‘Commanding Presence’ In Japan Generics Via Eisai Alliance
Hanmi Mulls New Trial Strategy As ZAI Lab Ends Olmutinib Partnership
Alteogen Eyes ASEAN, OIC Biosimilar Markets Via Malaysian JV
Interview: C4XD Chief Sees Indivior Pact As First Of Many
USV Primes German Base With Juta Acquisition
Takeda's Interest Likely To Flush Out Further Shire Suitors
GSK Gains Clarity For Pharma Focus Through Novartis Consumer JV Buy
Pipeline Watch: Phase III Progress With Avelumab, Ixekizumab And Eravacycline
Deal Watch: Zymeworks Adds Daiichi To List Of Partners In I-O Cross Collaboration

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC100678

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel